Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Burkitt Lymphoma 19Lymphoma, Large B-Cell, Diffuse 17Multiple Myeloma 15Lymphoma, Non-Hodgkin 13Lymphoma, Follicular 11Lymphoma 11Leukemia, Myeloid, Acute 11Recurrence 10Ovarian Neoplasms 9Lymphoma, B-Cell 9Myelodysplastic Syndromes 8Pancreatic Neoplasms 7Leukemia, Lymphocytic, Chronic, B-Cell 7Leukemia 7Lymphoma, Mantle-Cell 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Hodgkin Disease 6Hematologic Neoplasms 6Breast Neoplasms 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasms 5Leukemia, Myelomonocytic, Chronic 5Triple Negative Breast Neoplasms 4Stomach Neoplasms 4Sarcoma, Ewing 4Sarcoma 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Osteosarcoma 4Lymphoma, Large-Cell, Anaplastic 4

Interventions

remdesivir 1fludarabine 1Standard of Care 1Specimen Handling 1Practice Guidelines as Topic 1Methods 1Interviews as Topic 1Educational Status 1Early Intervention, Educational 1Cyclophosphamide 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Autoimmune Diseases × Cyclophosphamide × 30 days × Clear all
NCT06193889 2026-05-15

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

Kyverna Therapeutics

Phase 2/3 Recruiting
66 enrolled

Autoimmune Diseases, Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡